Forendo: Dr. Csimma Board of Directors

Turku, Finland, September 16th, 2020: Forendo Pharma, a clinical-stage drug development company focusing on novel treatments in women's health, today announced that Dr Cristina Csimma has been appointed as Chair of the Board of Directors. Cristina brings with her deep expertise in the biopharmaceutical, venture capital, and academic sectors.

Takeover bid OncoDNA on IntegraGEN

9th July 2020 (7:45), Gosselies (Belgium) and Evry (France): OncoDNA SA and IntegraGen SA (Paris: ALINT) announce the signature on July 8th 2020 of an agreement under which the Belgian company OncoDNA will file today a friendly cash tender offer to purchase the shares of the French company IntegraGen, whose securities are admitted to trading on the Euronext Growth market of Euronext Paris, at a price per share of €2.20, valuing IntegraGen share capital at €14.5m1 for 100%.

SWORD Health’s digital MSK therapy

June 17th, 2020: Concordia Plan Services, a benefits provider for over 6,000 LCMS organizations worldwide, today announced that they will begin to offer their members access to SWORD Health's digital therapy programs for musculoskeletal pain.

SWORD Health: Key Leadership

June 15th, 2020: SWORD Health, a digital musculoskeletal and pulmonary therapy provider, today announced the appointment of seven accomplished leaders to their executive team:

DEARhealth: Chronic Disease Management Platform

VENICE, California., May 27th, 2020: DEARhealth Inc., a health tech company focused on AI-powered disease management, announced today the global launch of its DEARhealth platform in the Epic App Orchard online marketplace. Organizations using Epic, including health systems, hospitals, and clinics, can now access DEARhealth directly through the marketplace instead of traditional external integration, saving significant time, costs, and staff resources.

SWORD Health Extends to $17M

New York, February 27th, 2020: SWORD Health (SWORD), a tech-enabled provider of musculoskeletal care, today announced the addition of $9 million to their Series A investment, bringing their total Series A investment to $17 million.

Prothesenfüße aus dem 3D-Drucker

Munich, January 20th, 2020 – Prosthetic feet from the 3D printer are no longer an utopia, but reality. The combination of designing a foot in the computer and fast production through 3D printing creates a completely new ability to act, as Mercuris GmbH proves.

OncoDNA Closes Investment Round

Gosselies, Belgium – February 14th, 2020 – OncoDNA ("OncoDNA or "the Company"), the healthcare technology company making precision medicine a reality, today announced that it has completed a €19 million ($20 million) Series B equity financing.

Mecuris GmbH: New CEO at the helm

Munich, Germany / February 10th, 2020. – Successful Munich-based medical technology company Mecuris will be led by a new CEO, Peter Fröhlingsdorf (50), a renowned industry expert. Since the beginning of January this year, Fröhlingsdorf has been managing the business of the up-and-coming medtech scale-up. The main goal for this financial year is to lead the company from the start-up into the growth phase. The CEO's expertise and numerous years of industry know-how will be decisive in this process.

New Growth Funding Mecuris GmbH

Munich, Germany, January 13th, 2020 – German med-tech company Mecuris GmbH has successfully concluded a new funding round amounting to 3.6 million euros. In addition to the seed investors Bayern Kapital and High-Tech Gründerfonds (HTGF), the international investment company Mulcan, life science venture capital investor Vesalius Biocapital, and Sana Kliniken AG, one of the top five hospital chains in Germany, are once again also on board.